2022 ICCB & APOCB - Tang Prize Lecture

A- | A+


Official Webiste


Event 2022 ICCB & APOCB
Time November 7- 11, 2022
H.S.S. Building, Academia Sinica, Taipei Taiwan
Time and Venue for the Tang Prize Lecture

November 11, 2022
H.S.S. Building, Academia Sinica


Dr. Tadamitsu Kishimoto
2020 Tang Prize laureate in Biopharmaceutical Science


Interleukin 6: from Arthritis to COVID-19

Lecture Outline Interleukin-6 (IL-6) possesses the diverse biological activity that contributes to the maintenance of homeostasis. Emergent cases of infection or tissue injury induce rapidly production of IL-6 and activates host defense through the augmentation of acute phase proteins and immune responses. However, excessive IL-6 production and uncontrolled IL-6 receptor signaling have critical roles in disease pathogenesis. Over the years, therapeutic agents targeting IL-6 signaling, such as tocilizumab, a humanized anti-IL-6 receptor antibody, have shown remarkable efficacy for rheumatoid arthritis, Castleman`s disease, and juvenile idiopathic arthritis, and applicable diseases are continuously being reported. Emerging evidence has demonstrated the beneficial efficacy of tocilizumab for several types of acute inflammatory diseases including chimeric antigen receptor T-cell therapy-induced cytokine storms and coronavirus diseases 2019 (COVID-19). Here, we refocus attention on the biology of IL-6 and summarize the distinct pathological roles of IL-6 signaling in several acute and chronic inflammatory diseases.